foselutoclax

AssetAlso UBX1325

Senolytic BCL-xL inhibitor given into the eye to clear senescent cells from diseased retinal vessels

Stage: Discontinued
Modality: Small molecule
Target: Cellular senescence; 2
Indications: 0
Trials: 1
Developer

Indications

2

Diabetic macular edema
Discontinued, Completed, sec.gov, Aug 11, 2025
Neovascular age-related macular degeneration
Discontinued, Completed, sec.gov, Aug 11, 2025

In the full profile

Targets and what it contains3
Owner and partners1
Evidence for its targets3
Competitors12
Aging relevance1
Signals5

Every asset’s record: target, stage, trials and the evidence behind it.